|
Cost savings boost Vectura's cash resources
Reuters L) said cost savings had put it in a stronger position than expected as it awaits trial results and European approvals for its medicine to treat asthma. The British company, which has developed what is potentially a generic rival to GlaxoSmithKline's … |
View full post on asthma – Google News